Group 1 - The TPD (Targeted Protein Degradation) sector is experiencing rapid development, particularly in the area of protein degradation technology for autoimmune diseases, with key small molecule targets such as STAT6, IRAK4, IRF5, VAV1, NLRP3, and NEK7 gaining attention [1] - These targets are showing excellent efficacy and safety in clinical or preclinical stages, paving new pathways for the treatment of autoimmune diseases [1] - Data readouts for numerous autoimmune TPD targets are expected to begin in 2026, potentially entering critical clinical phases [1] Group 2 - In the medical device industry, there is a focus on inventory replenishment and bidding processes, particularly for surgical robots and endoscopes [1] - Attention is also directed towards innovative consumables benefiting from centralized procurement, such as neurointerventional, peripheral interventional, and electrophysiological products [1] - The Guotai Healthcare ETF (159377) tracks the Chuangyi Medicine Index (399275), which includes listed companies engaged in biopharmaceuticals, chemical pharmaceuticals, traditional Chinese medicine, and medical services, reflecting the overall performance of innovative biopharmaceutical-related securities [1]